Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Main Article Content

Andrew F Alexis
Paul S Yamauchi
Tina Lin
Gina Martin

Keywords

psoriasis, tazarotene, halobetasol

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496‑509.

2. Cohen SN, et al. Clin Exp Dermatol. 2012;37 Suppl 1:13‑18.

3. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643‑659.

4. Lam LH, et al. J Drugs Dermatol. 2016; 15(8):945‑948.

5. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855‑861.